Thermo Fisher Scientific launches CorEvitas Obesity Registry
Registry developed to advance real-world evidence in treatment outcomes
13 Jan 2026
Thermo Fisher Scientific has announced the enrollment of the first patient in the new PPD™ CorEvitas™ Obesity Registry. This prospective, observational registry will generate real-world evidence on the long-term effectiveness, safety and patient experience associated with obesity management therapies, including anti-obesity medications.
By collecting insights directly from both clinicians and patients, the registry will provide critical insights into treatment patterns, adherence, satisfaction and clinical outcomes, including anthropomorphic measures, across diverse care settings.
The Registry is designed to collect detailed physician and patient-reported outcomes to better understand disease progression, treatment response and the challenges patients encounter along their care journey. Insights from the registry aim to inform clinical practice, guide future research and support the development of evidence-based strategies for obesity management.
The initiative marks the 15th independent registry established under PPD™ CorEvitas™ Clinical Registries, part of the PPD clinical research business of Thermo Fisher Scientific.
“The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice,” said Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries, Thermo Fisher Scientific. “Insights generated from this robust, real-world evidence base will inform the healthcare community on treatment effectiveness, safety and the patient experience associated with obesity care, which will advance care for millions living with the condition.”